Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-51. (Canceled).

52. (Previously presented) A mouse comprising homozygous disruption of TLR2 gene in its genome, wherein such disruption results in no production of endogenous TLR2 protein, and wherein said mouse exhibits the phenotype of being unresponsive to bacterial cell component(s) that is a lipoprotein/lipopeptide.

53. (Previously presented) The mouse according to claim 52, wherein a lipoprotein/lipopeptide is a macrophage-activating lipopeptide obtained from bacteria which belong to Mycoplasma.

54. (Previously presented) The mouse according to claim 52 that is further unresponsive to peptidoglycan as a bacterial cell component.

55. (Previously presented) The mouse according to claim 52 that is further hyporesponsive to a cell wall fraction of Gram-positive bacteria.

56-58. (Canceled)

59. (Previously presented) A mouse comprising homozygous disruption of MyD88 gene in its genome, wherein such disruption results in no production of endogenous MyD88 protein, and wherein said mouse exhibits the phenotype of being unresponsive to bacterial cell component(s) that is a lipoprotein/lipopeptide.

60. (Previously presented) The mouse according to claim 59, wherein a lipoprotein/lipopeptide is a macrophage-activating lipopeptide obtained from bacteria which belong to Mycoplasma.

61. (Previously presented) The mouse according to claim 59 that is further unresponsive to peptidoglycan as a bacterial cell component.

62. (Previously presented) The mouse according to claim 59 that is further unresponsive to a cell wall fraction of Gram-positive bacteria.

63. (Previously presented) The mouse according to claim 59 that is further unresponsive to endotoxin as a bacterial cell component.

64. (Previously presented) The mouse according to claim 59 that is further unresponsive to lipoteichoic acid as a bacterial cell component.

65. (Previously presented) The mouse according to claim 59 that is further unresponsive to Mycobacterium tuberculosis lysate as a bacterial cell component.